Table 2.
Total IGF-1, IGFBP-3, and IGF-1/IGFBP-3 levels by demographics, health characteristics, and medical conditions at baseline.
| Variable | Total IGF-1 | IGFBP-3 | IGF-1/IGFBP-3 | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Yes | No | p | Yes | No | p | Yes | No | p | |
| Cognitive Impairment* | |||||||||
| N | 88 | 1,530 | 88 | 1,534 | 88 | 1,530 | |||
| Median (IQR) | 106.5 (85.0. 143.5) | 118.0 (91.0, 149.0) | 0.114 | 3.1 (2.7, 3.8) | 3.5 (2.9, 4.1) | <0.001 | 36.5 (29.2, 47.7) | 34.3 (28.4, 41.7) | 0.114 |
| Hypertension | |||||||||
| N | 1,002 | 575 | 1,002 | 579 | 1,002 | 575 | |||
| Median (IQR) | 116.0 (88.0, 147.0) | 121.0 (96.0, 149.0) | 0.005 | 3.3 (2.7, 4.0) | 3.7 (3.1, 4.3) | <0.001 | 35.2 (28.7, 42.9) | 33.2 (27.8, 40.0) | 0.003 |
| Diabetes | |||||||||
| N | 265 | 1,316 | 265 | 1,320 | 265 | 1,316 | |||
| Median (IQR) | 106.0 (83.0, 145.0) | 119.0 (93.0, 149.0) | <0.001 | 3.1 (2.5, 3.7) | 3.5 (2.9, 4.2) | <0.001 | 35.7 (29.0, 44.6) | 34.2 (28.2, 41.3) | 0.036 |
| CABG | |||||||||
| N | 90 | 1,489 | 90 | 1,493 | 90 | 1,489 | |||
| Median (IQR) | 116.5 (94.5, 141.5) | 118.0 (90.0, 149.0) | 0.503 | 3.0 (2.5, 3.4) | 3.5 (2.9, 4.1) | <0.001 | 39.2 (32.2, 45.2) | 34.0 (28.1, 41.4) | <0.001 |
| Myocardial infarction | |||||||||
| N | 212 | 1,364 | 212 | 1,368 | 212 | 1,364 | |||
| Median (IQR) | 118.0 (95.0, 152.0) | 117.5 (90.0, 148.0) | 0.800 | 3.1 (2.5, 3.7) | 3.5 (2.9, 4.2) | <0.001 | 38.5 (32.2, 47.2) | 33.6 (27.9, 41.1) | <0.001 |
| Stroke | |||||||||
| N | 57 | 1,521 | 57 | 1,525 | 57 | 1,521 | |||
| Median (IQR) | 129.5 (93.0, 149.0) | 118.0 (91.0, 149.0) | 0.617 | 3.5 (2.9, 3.9) | 3.5 (2.8, 4.1) | 0.281 | 35.8 (29.4, 46.3) | 34.3 (28.2, 41.7) | 0.152 |
| Cancer (any) | |||||||||
| N | 331 | 1,026 | 331 | 1,029 | 331 | 1,026 | |||
| Median (IQR) | 115.0 (90.0, 146.0) | 116.0 (90.0, 146.0) | 0.934 | 3.4 (2.8, 3.9) | 3.4 (2.8, 4.1) | 0.587 | 34.7 (28.7, 43.4) | 34.5 (28.3, 41.7) | 0.517 |
| Depression (BDI ≥ 13) | |||||||||
| N | 123 | 1,477 | 123 | 1,481 | 123 | 1,477 | |||
| Median (IQR) | 121.0 (89.0, 152.0) | 118.0 (91.0, 149.0) | 0.809 | 3.4 (2.8, 4.0) | 3.5 (2.9, 4.1) | 0.456 | 33.3 (28.4, 43.3) | 34.5 (28.4, 41.7) | 0.881 |
| Gait speed < 1 m/s | |||||||||
| N | 413 | 1,085 | 413 | 1,089 | 413 | 1,085 | |||
| Median (IQR) | 110.0 (85.0, 143.0) | 121.0 (95.0, 151.0) | <0.001 | 3.2 (2.6, 3.9) | 3.6 (3.0, 4.2) | <0.001 | 34.3 (27.8, 42.8) | 34.5 (28.6, 41.7) | 0.920 |
| Hormone replacement therapy (women) | |||||||||
| N | 74 | 660 | 75 | 661 | 74 | 660 | |||
| Median (IQR) | 98.0 (70.0, 138.0) | 109.5 (85.0, 141.0) | 0.058 | 3.8 (3.0, 4.4) | 3.7 (3.1, 4.4) | 0.507 | 26.8 (22.0, 33.9) | 29.9 (24.6, 35.2) | 0.014 |
*
Cognitive impairment defined as z global score < −1.0 SD below the age-specific norm
BMI, body mass index; CCI, Charlson comorbidity index; CABG, coronary artery bypass grafting; BDI, Beck Depression Inventory; HRT, hormone replacement therapy